Iovance Biotherapeutics closes $172.5M public offering of 23M shares at $7.50/share

IOVANCE BIOTHERAPEUTICS, INC.

Closed underwritten public offering of 23,000,000 shares at $7.50 per share.
Gross proceeds $172.5M; net proceeds expected ~$161.4M after discounts and expenses.
Proceeds to fund lifileucel commercial launch prep, iCTC manufacturing, and clinical programs.
Full exercise of underwriters' option to purchase an additional 3 million shares.
Goldman Sachs & Co. LLC and Jefferies LLC acted as joint lead book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.